Cite
Brentuximab vedotin (BV) versus physician’s choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
MLA
Steven M. Horwitz, et al. “Brentuximab Vedotin (BV) versus Physician’s Choice (PC) of Methotrexate or Bexarotene in Adult Patients with Previously Treated CD30-Positive Cutaneous T-Cell Lymphoma (CTCL; Mycosis Fungoides [MF] or Primary Cutaneous Anaplastic Large Cell Lymphoma [PcALCL]): Final Time to next Therapy (TTNT) Results from the Phase 3 ALCANZA Study.” European Journal of Cancer, vol. 119, Jan. 2019, p. S31. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8827a2fb72464a274fec2904b955c2c6&authtype=sso&custid=ns315887.
APA
Steven M. Horwitz, Meredith Little, Lauren Pinter-Brown, Herbert Eradat, Pablo L. Ortiz-Romero, Reinhard Dummer, José Antonio Sanches, Youn H. Kim, Oleg E. Akilov, Oliver Bechter, Madeleine Duvic, Sean Whittaker, Veronica Bunn, Lisa Brown, Pier Luigi Zinzani, Larisa J. Geskin, Pietro Quaglino, Julia Scarisbrick, H. Miles Prince, & Julie Lisano. (2019). Brentuximab vedotin (BV) versus physician’s choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study. European Journal of Cancer, 119, S31.
Chicago
Steven M. Horwitz, Meredith Little, Lauren Pinter-Brown, Herbert Eradat, Pablo L. Ortiz-Romero, Reinhard Dummer, José Antonio Sanches, et al. 2019. “Brentuximab Vedotin (BV) versus Physician’s Choice (PC) of Methotrexate or Bexarotene in Adult Patients with Previously Treated CD30-Positive Cutaneous T-Cell Lymphoma (CTCL; Mycosis Fungoides [MF] or Primary Cutaneous Anaplastic Large Cell Lymphoma [PcALCL]): Final Time to next Therapy (TTNT) Results from the Phase 3 ALCANZA Study.” European Journal of Cancer 119 (January): S31. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8827a2fb72464a274fec2904b955c2c6&authtype=sso&custid=ns315887.